Michael Tao
Overview
Explore the profile of Michael Tao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Al-Sadawi M, Tao M, Zhang D, Wanamaker B, Deshmukh A, Ghannam M, et al.
Cardiovasc Revasc Med
. 2024 Nov;
PMID: 39609238
Background: Coronary chronic total occlusion (CTO) can result in ischemic cardiomyopathy which may create substrate supportive of ventricular arrhythmias (VA). The purpose of this meta-analysis is to evaluate the association...
2.
Frye J, Tao M, Gupta S, Gier C, Masson R, Rahman T, et al.
Cardiovasc Revasc Med
. 2024 Jul;
70:23-33.
PMID: 38965019
Background: Acute myocardial infarction complicated by cardiogenic shock (AMI-CS) is a major cause of morbidity and mortality. Although mechanical circulatory support (MCS) is an increasingly utilized therapeutic option in AMI-CS,...
3.
Al-Sadawi M, Henriques M, Gier C, Tao M, Almasry I, Singh A, et al.
JACC Adv
. 2024 Jun;
2(7):100561.
PMID: 38939490
No abstract available.
4.
Lazar D, Tao M, Matievich W, Kastanos K, Dunn T
J Diabetes Sci Technol
. 2024 Jun;
:19322968241260038.
PMID: 38907649
Background: Increasing numbers of individuals with diabetes are adopting use of continuous glucose monitoring (CGM) in their daily self-management. Many of these individuals have advanced heart disease. Implantable cardioverter defibrillator...
5.
Al-Sadawi M, Tao M, Dhaliwal S, Goldschmit M, Tam E, Mann N
High Blood Press Cardiovasc Prev
. 2024 May;
31(3):239-249.
PMID: 38740725
Introduction: Hypertension (HTN) is a co-morbidity that is commonly associated with heart failure with preserved ejection fraction (HFpEF). However, it remains unclear whether treatment of hypertension in HFpEF patients is...
6.
Al-Sadawi M, Tao M, Dhaliwal S, Radakrishnan A, Liu Y, Gier C, et al.
Cardiovasc Revasc Med
. 2024 Mar;
65:88-97.
PMID: 38503643
Background: Revascularization in patients with left ventricular (LV) dysfunction has been a subject of ongoing uncertainty and conflicting results. This is further complicated by factors including viability, severity of LV...
7.
Tao M, Dhaliwal S, Ghosalkar D, Sheng S, Dianati-Maleki N, Tam E, et al.
Int J Cardiol Heart Vasc
. 2024 Feb;
51:101339.
PMID: 38371310
Background: Cardiac magnetic resonance imaging (CMR) based T1 mapping and extracellular volume fraction (ECV) are powerful tools for identifying myocardial fibrosis. This systematic review and -analysis aims to characterize the...
8.
Gier C, Kalogeropoulos A, Henriques M, Al-Sadawi M, Aslam F, Tao M, et al.
J Am Heart Assoc
. 2024 Jan;
13(2):e029788.
PMID: 38214290
No abstract available.
9.
Al-Sadawi M, Gier C, Tao M, Henriques M, Kim P, Aslam F, et al.
Am J Cardiol
. 2024 Jan;
213:55-62.
PMID: 38183873
Background: The benefit of implantable cardioverter-defibrillator (ICD) therapy is controversial in patients who have heart failure with improved left ventricular ejection fraction (EF) to >35% after implantation (HFimpEF). Methods: Databases...
10.
Al-Sadawi M, Tao M, Dhaliwal S, Masson R, Bhagat A, Parikh P, et al.
Cardiovasc Revasc Med
. 2024 Jan;
62:66-72.
PMID: 38176961
Background: The beneficial role of dual anti-platelet therapy (DAPT) in coronary artery disease is well established. However, there is limited data describing the effects of DAPT in patients with atherosclerotic...